The workforce reduction is expected to be substantially completed on December 31, 2024.In connection with the reduction in work...

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has t...

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, inc...

Piper Sandler analyst Edward Tenthoff downgrades Kronos Bio (NASDAQ:KRON) from Overweight to Neutral and lowers the price ta...

TD Cowen analyst Floris Van Dijkum downgrades Kronos Bio (NASDAQ:KRON) from Buy to Hold.

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by...

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between ...

Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and autoimmu...

Piper Sandler analyst Edward Tenthoff reiterates Kronos Bio (NASDAQ:KRON) with a Overweight and maintains $6 price target.

– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and originates from i...

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of mul...